Track topics on Twitter Track topics that are important to you
The purpose of this study is to establish and validate a scale/model that can be used in the evaluation of the duration of time and factors between short term hospital treatment and subsequent relapse periods in patients with schizoaffective/schizophreniform disorders.
This is an epidemiological, multicentre, observational, cross-sectional prospective study. This study is carried out in Spain. The primary objectives are to establish and validate a scale/model which predicts, depending on the risk factors, the short-term period of time before relapse of a patient given hospital discharge in a Short-Term Psychiatric Hospitalization Unit or Acute Unit, in Spain, to confirm the determination of the most important factors regarding number of hospital re-admissions and to recognize and assess the repercussion of the clinical profile of patients with schizophrenia, and schizoaffective/schizophreniform disorders who suffer relapses (predictive model in a cross-sectional, prospective evaluation). This study is observational and non-product specific. The illness or disorder under study is schizophrenia and schizoaffective/shizophreniform disorder according to DSM-IV criteria. The population under study is the following: patients attended to in Short-Term Psychiatric Hospitalization Units or Acute Units. Approximately 2,000 patients are estimated (see sample size calculation). The objectives require the collection of data referring to all patients seen and discharged for three consecutive months, during the second quarter of 2006, in order to achieve the desired sample size. It is therefore necessary to incorporate so many Short-Term Psychiatric Hospitalization Units or Acute Units in the project, as well as to include 300 consultant psychiatric investigators in practice at the time of data collection and who are able to assist with recruitment. This study will be performed under normal conditions of medical conduct and in accordance with clinical practice. It will consist of the collection of background data (age intervals, sex, maximum level of education achieved, degree of family support, substance consumption, stressful events, type of schizophrenia according to DSM-IV, etc). No extra tests will be performed during the study, nor whilst completing the electronic Case Report Form (e-CRF). All AE and all SAE will be recorded on the e-CRF. This data will be kept at the centre until it is sent to Janssen-Cilag. Janssen-Cilag will prepare a final report of the study including all AE and SAE. All SAE occurring with the administration of Janssen-Cilag drugs must be reported by the doctor within 24 hour of their knowledge to the person responsible for pharmacovigilance designed by Janssen-Cilag Spain using the Serious Adverse Event Report Form. Pregnancies are treated as if they were SAEs during the study. All pregnancies occurring with the administration of Janssen-Cilag drugs must be reported by the doctor within 24 hour of their knowledge to the person responsible for pharmacovigilance designed by Janssen-Cilag Spain using the Pregnancy Report Form.
Janssen-Cilag S.A., (formerly Janssen Sp)
Published on BioPortfolio: 2014-08-27T03:43:15-0400
The purpose of this study is to see if differences exist in outcome in patients with schizophrenia or schizoaffective disorder who were switched from other antipsychotics to ziprasidone.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an a...
To determine whether the changes in BMI produced in subjects with Bipolar Disorder (BD) and Schizoaffective Disorder (SA) by 12 months of treatment with clozapine, can be diminished after ...
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
This randomized, double-blind, placebo-controlled parallel group study will assess the effect on biomarkers measures of cognitive dysfunction, the clinical efficacy and safety of RO4917383...
Schizophrenia and schizoaffective disorder are chronic and debilitating psychiatric disorders. The present study was designed to determine DNA damage in patients with schizophrenia and schizoaffective...
The geniuses Robert Schumann and Vincent Van Gogh show striking similarities both in the longitudinal nature of the progression of their illnesses, and the symptoms they experienced. There have been p...
To evaluate the coherence values of the cortical bands in patients with first episode schizophrenia and schizoaffective disorder during the performance of a mental arithmetic task.
There is growing interest in oxytocin as a putative treatment for various psychiatric disorders including major depressive disorder, bipolar disorder and schizophrenia/schizoaffective disorder. Howeve...
A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in MENTAL RETARDATION and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
A disorder whose predominant feature is a loss or alteration in physical functioning that suggests a physical disorder but that is actually a direct expression of a psychological conflict or need.
A personality disorder whose essential feature is a pervasive pattern of disregard for, and violation of, the rights of others that begins in childhood or early adolescence and continues into adulthood. The individual must be at least age 18 and must have a history of some symptoms of CONDUCT DISORDER before age 15. (From DSM-IV, 1994)
A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
A disorder beginning in childhood. It is marked by the presence of markedly abnormal or impaired development in social interaction and communication and a markedly restricted repertoire of activity and interest. Manifestations of the disorder vary greatly depending on the developmental level and chronological age of the individual. (DSM-IV)
Psychiatry is the study of mental disorders and their diagnosis, management and prevention. Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...
Schizophrenia is a common serious long-term mental health condition that affects 5 in 1000 in the UK. It causes a range of different psychological symptoms; hallucinations, delusions, muddled thoughts based on the hallucinations or delusions and ch...